Hikma receives FDA approval for Leucovorin Calcium Injection
5/4/2016 12:00:00 AM
WestWardProduct
News Icon Image

Hikma receives FDA approval for Leucovorin Calcium Injection 

 

London, 4 May 2016 –  Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its supplemental Abbreviated New Drug Application  (sANDA) for Leucovorin Calcium Injection, 350 mg Single-use vial has been approved by the U.S. Food and Drug Administration (FDA).

 

Leucovorin Calcium Injection is used for the prevention and treatment of certain blood cell disorders, and can be used in conjunction with other oncology drugs for the treatment of colorectal cancer.  According to IMS Health, U.S. sales of Leucovorin Calcium Injection were approximately $35 million for the 12 months ending March 2016, of which the 350 mg presentation represented around $19 million

 

Said Darwazah, Chairman and CEO of Hikma, said, “We are very pleased this product has been approved for the US market. We continue to leverage our strong R&D, regulatory and high-quality manufacturing facilities and remain committed to prioritising the re-introduction of Bedford products for patients in need.”

 

-- ENDS --


Enquiries
Hikma Pharmaceuticals PLC

 Susan Ringdal, VP Corporate Strategy and Investor Relations 
 +44 (0)20 7399 2760/ +44 7776 477050
 Zeena Murad, Investor Relations Manager
 +44 (0)20 7399 2768/ +44 7771 665277

 

FTI Consulting

 Ben Atwell/ Matthew Cole           
+44 (0)20 3727 1000 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa (MENA) and Europe.  In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million.  

  • WW_LOGO
  • West-Ward Pharmaceuticals Corp.

    401 Industrial Way West

    Eatontown, New Jersey 07724-2206

  • Hikma Logo
  • West-Ward Pharmaceuticals Corp. is a subsidiary of Hikma Pharmaceuticals PLC

  • VAWD Logo
  • 2009-Current West-Ward Pharmaceuticals Corp. Memphis’ distribution center is the first distribution center to be awarded “Verified-Accredited Wholesale Distributors® (VAWD®) accreditation” by The National Association of Boards of Pharmacy® (NABP®).

    Click Here for more information